Literature DB >> 1764386

Phase II trial of didox in advanced breast cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee.

R D Rubens1, S B Kaye, M Soukop, C J Williams, M H Brampton, A L Harris.   

Abstract

Fourteen patients with advanced breast cancer were treated with the ribonucleotide reductase inhibitor didox 6 g m-2 given by intravenous infusion over 36 h every 3 weeks. None responded and toxicity was minimal. Possibilities for the more effective use of this agent are discussed.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1764386      PMCID： PMC1977835          DOI： 10.1038/bjc.1991.488

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  4 in total

1.  Ribonucleotide reductase and cell proliferation. I. Variations of ribonucleotide reductase activity with tumor growth rate in a series of rat hepatomas.

Authors:  H L Elford; M Freese; E Passamani; H P Morris
Journal:  J Biol Chem       Date:  1970-10-25       Impact factor: 5.157

Review 2.  Inhibition of nucleoside diphosphate reductase by hydroxybenzohydroxamic acid derivatives.

Authors:  H L Elford; B van't Riet
Journal:  Pharmacol Ther       Date:  1985       Impact factor: 12.310

3.  New ribonucleotide reductase inhibitors with antineoplastic activity.

Authors:  H L Elford; G L Wampler; B van't Riet
Journal:  Cancer Res       Date:  1979-03       Impact factor: 12.701

4.  Assessment of response to therapy in advanced breast cancer.

Authors:  J L Hayward; P P Carbone; J C Heusen; S Kumaoka; A Segaloff; R D Rubens
Journal:  Br J Cancer       Date:  1977-03       Impact factor: 7.640
  4 in total
  7 in total

1.  Didox (3,4-dihydroxybenzohydroxamic acid) suppresses IL-33-induced cytokine production in primary mouse mast cells.

Authors:  Heather L Caslin; Jamie Josephine Avila McLeod; Andrew J Spence; Amina Abdul Qayum; Elizabeth Motunrayo Kolawole; Marcela T Taruselli; Anuya Paranjape; Howard L Elford; John J Ryan
Journal:  Cell Immunol       Date:  2017-07-11       Impact factor: 4.868

Review 2.  Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present.

Authors:  Sarah E Huff; Jordan M Winter; Chris G Dealwis
Journal:  Biomolecules       Date:  2022-06-10

3.  Biochemical and antitumor activity of trimidox, a new inhibitor of ribonucleotide reductase.

Authors:  T Szekeres; K Gharehbaghi; M Fritzer; M Woody; A Srivastava; B van't Riet; H N Jayaram; H L Elford
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

4.  Ribonucleotide reductase inhibitors hydroxyurea, didox, and trimidox inhibit human cytomegalovirus replication in vitro and synergize with ganciclovir.

Authors:  Sukhada Bhave; Howard Elford; Michael A McVoy
Journal:  Antiviral Res       Date:  2013-08-06       Impact factor: 5.970

5.  Didox (3,4-dihydroxybenzohydroxamic acid) suppresses IgE-mediated mast cell activation through attenuation of NFκB and AP-1 transcription.

Authors:  Jamie Josephine Avila McLeod; Heather L Caslin; Andrew J Spence; Elizabeth M Kolawole; Amina Abdul Qayum; Anuya Paranjape; Marcela Taruselli; Tamara T Haque; Kasalina N Kiwanuka; Howard L Elford; John J Ryan
Journal:  Cell Immunol       Date:  2017-09-21       Impact factor: 4.868

Review 6.  Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy?

Authors:  Mukundan Baskar Mannargudi; Subrata Deb
Journal:  J Cancer Res Clin Oncol       Date:  2017-06-17       Impact factor: 4.322

Review 7.  Update on the Role of NFκB in Promoting Aggressive Phenotypes of Estrogen Receptor-Positive Breast Cancer.

Authors:  Emily Smart; Svetlana E Semina; Jonna Frasor
Journal:  Endocrinology       Date:  2020-10-01       Impact factor: 4.736
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.